Screening of the promising direct thrombin inhibitors from haematophagous organisms. Part I: Recombinant analogues and their antithrombotic activity in vitro
This is a collaborative work of researchers from the Laboratory of Biopharmaceutical Technologies of the IBCh RAS and Biological Testing Laboratory of the BIBCh RAS. Its goal is the development and testing of new anticoagulants from haematophagous organisms. Haemadin from the leech Haemadipsa sylvestris, variegin from the tick Amblyomma variegatum, and anophelin from Anopheles albimanus were chosen as the most promising anticoagulants. We have developed a method for the biotechnological production of these recombinant peptides with pharmaceutical purity. As a reference standard, we have used the recombinant hirudin-1 from Hirudo medicinalis (desirudin), which is the active substance of the FDA-approved drug Iprivask (Aventis Pharmaceuticals, USA). The anticoagulant activities of these peptides were compared using the thrombin amidolytic activity assay and detection of the prolongation of coagulation time (thrombin time, prothrombin time, and activated partial thromboplastin time) in mouse and human plasma. The article was published in the journal Biomedicines (IF 6.081).
june 21, 2022